To evaluate the therapeutic efficacy of passive cellular immunotherapy for glioma, a total of 979 patients were assigned to the meta-analysis. PubMed and the Cochrane Central Register of Controlled Trials were searched initially from February 2018 and updated in April 2019. The overall survival (OS) rates and Karnofsky performance status (KPS) values of patients who underwent passive cellular immunotherapy were compared to those of patients who did not undergo immunotherapy. The proportion of survival rates was also evaluated in one group of clinical trials. Pooled analysis was performed with random- or fixed-effects models. Clinical trials of lymphokine-activated killer cells, cytotoxic T lymphocytes, autologous tumor-specific T lymphocytes, chimeric antigen receptor T cells, cytokine-induced killer cells, cytomegalovirus-specific T cells, and natural killer cell therapies were selected. Results showed that treatment of glioma with passive cellular immunotherapy was associated with a significantly improved 0.5-year OS (p = 0.003) as well as improved 1-, 1.5-, and 3-year OS (p ≤ 0.05). A meta-analysis of 206 patients in one group of clinical trials with 12-month follow-up showed that the overall pooled survival rate was 37.9% (p = 0.003). Analysis of KPS values demonstrated favorable results for the immunotherapy arm (p < 0.001). Thus, the present meta-analysis showed that passive cellular immunotherapy prolongs survival and improves quality of life for glioma patients, suggesting that it has some clinical benefits.

中文翻译：

---

评估被动细胞免疫疗法对神经胶质瘤患者的疗效。

为了评估被动细胞免疫疗法对神经胶质瘤的治疗效果，共有 979 名患者被分配到荟萃分析。PubMed 和 Cochrane Central Register of Controlled Trials 最初从 2018 年 2 月开始检索，并于 2019 年 4 月更新。将接受被动细胞免疫治疗的患者的总生存 (OS) 率和 Karnofsky 体能状态 (KPS) 值与接受被动细胞免疫治疗的患者进行比较。没有接受免疫治疗。在一组临床试验中也评估了存活率的比例。使用随机或固定效应模型进行合并分析。淋巴因子激活的杀伤细胞、细胞毒性 T 淋巴细胞、自体肿瘤特异性 T 淋巴细胞、嵌合抗原受体 T 细胞、细胞因子诱导的杀伤细胞、巨细胞病毒特异性 T 细胞的临床试验，并选择了自然杀伤细胞疗法。结果表明，用被动细胞免疫疗法治疗胶质瘤与显着改善 0.5 年 OS 相关。p  = 0.003）以及改善的 1 年、1.5 年和 3 年 OS（p  ≤ 0.05）。对一组临床试验中的 206 名患者进行 12 个月随访的荟萃分析显示，总合并生存率为 37.9%（p  = 0.003）。KPS 值的分析表明免疫治疗组的结果良好 ( p  < 0.001)。因此，本荟萃分析表明，被动细胞免疫疗法可延长胶质瘤患者的生存期并提高生活质量，表明它具有一些临床益处。